Results 121 to 130 of about 143,566 (359)

Dendritic cell vaccine induces antigen-specific CD8+ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade

OncoImmunology, 2018
The success of immune checkpoint blockade has unequivocally demonstrated that anti-tumor immunity plays a pivotal role in cancer therapy. Because endogenous tumor-specific T-cell responsiveness is essential for the success of checkpoint blockade ...
Koji Nagaoka, Akihiro Hosoi, Tamaki Iino, Yasuyuki Morishita, Hirokazu Matsushita, Kazuhiro Kakimi   +5 more
doaj   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Alterations of immune response of non-small lung cancer with azacytidine [PDF]

, 2013
Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We have undertaken a genomics based, hypothesis driving, approach to query an emerging potential that epigenetic therapy may sensitize to immune checkpoint therapy targeting
Baylin, Stephen B, Brahmer, Julie R, Brock, Malcolm V, Carvajal, Richard D, De Meyer, Tim, Du, Zhengzong, Easton, Keith, Easwaran, Hariharan, Jones, Peter A, Juergens, Rosalyn A, Koch, Alexander, Laird, Peter W, Mohammad, Helai P, Pardoll, Drew, Parsana, Princy, Rodgers, Kristen, Rudin, Charles M, Taube, Janis M, Topalian, Suzanne L, Tsai, Salina, Tykodi, Scott S, Van Criekinge, Wim, Vendetti, Frank, Wang, Wei, Weisenberger, Daniel J, Wrangle, John, Yen, Ray-Whay, Zahnow, Cynthia A   +27 more
core   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Boosting cancer immunotherapy: drug delivery systems leveraging ferroptosis and immune checkpoint blockade

Frontiers in Immunology
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, significantly improving outcomes for various malignancies. Despite their clinical success, only a subset of patients benefits from ICIs treatment, underscoring the need for ...
Ting Zhang, Fanlin Gu, Wei Lin, Haiyan Shao, Aiguo Jiang, Xingang Guan   +5 more
doaj   +1 more source

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. [PDF]

, 2018
Regulatory T cells (Tregs) are critical for maintaining immune homeostasis, but their presence in tumor tissues impairs anti-tumor immunity and portends poor prognoses in cancer patients.
Abnousian, Arbi, Bluestone, Jeffrey A, DuPage, Michel, Fong, Lawrence, Harwin, Tory, Mahuron, Kelly, Pagani, Massimiliano, Pai, Chien-Chun, Quiros, Jason, Ranzani, Valeria, Rosenblum, Michael D, Silveria, Stephanie, Van Gool, Frederic, Wang, David, Young, Arabella   +14 more
core   +2 more sources

Supplementary figure legends from Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8⁺ T-Cell–Dependent Tumor Activity

, 2023
Tsubasa Watanabe, Simone Gaedicke, Elena Guffart, Elke Firat, Gabriele Niedermann   +4 more
openalex   +1 more source

Immune Checkpoint Blockade for Breast Cancer [PDF]

, 2018
An effective antitumor immune response requires interaction between cells of the adaptive and innate immune system. Three key elements are required: generation of activated tumor-directed T cells, infiltration of activated T cells into the tumor microenvironment, and killing of tumor cells by activated T cells.
April, Swoboda, Rita, Nanda
openaire   +2 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source